Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 23 2025
0mins
Should l Buy DTIL?
Source: Newsfilter
FDA Orphan Drug Designation: Precision BioSciences has received Orphan Drug Designation from the FDA for its gene therapy PBGENE-DMD, aimed at treating Duchenne muscular dystrophy (DMD), highlighting the urgent need for effective treatments in this area.
Clinical Development Plans: The company is advancing towards clinical trials with initial data expected in 2026, following successful preclinical studies that demonstrated significant functional improvements in a mouse model of DMD.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DTIL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DTIL
Wall Street analysts forecast DTIL stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 7.440
Low
30.00
Averages
45.00
High
60.00
Current: 7.440
Low
30.00
Averages
45.00
High
60.00
About DTIL
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Precision BioSciences Presents New Hepatitis Treatment Data
- Clinical Trial Progress: Precision BioSciences will present new clinical biopsy data from the ELIMINATE-B trial at the 2026 EASL Congress, demonstrating for the first time that PBGENE-HBV can eliminate cccDNA in the livers of chronic hepatitis B patients, marking a significant breakthrough that may offer hope for a cure.
- Therapeutic Potential: PBGENE-HBV is the world's first clinical trial targeting cccDNA through gene editing, designed to eliminate the root cause of chronic hepatitis B, and has received Fast Track designation from the FDA, highlighting its potential importance in treatment.
- Conference Highlights: The study will be showcased in a poster presentation on May 27, 2026, with abstract number LB26-51656, expected to attract significant attention and potentially boost investor confidence in the company's future developments.
- Market Outlook: Given the urgent need for effective treatments among chronic hepatitis B patients, the success of PBGENE-HBV could significantly enhance Precision BioSciences' competitiveness in the biopharmaceutical market, further solidifying its leadership position in the gene editing field.
See More
Precision BioSciences Expands ELIMINATE-B Trial into France and Romania
- Clinical Trial Expansion: Precision BioSciences has received Clinical Trial Application approval to expand the ELIMINATE-B trial into France and Romania, which is expected to significantly increase patient enrollment and support the clinical execution of PBGENE-HBV.
- Global Footprint Enhancement: This expansion adds multiple clinical trial sites in Europe to the ELIMINATE-B trial, including the UK, Moldova, New Zealand, and the US, thereby enhancing the company's international presence and influence.
- Increased Treatment Potential: PBGENE-HBV is the first gene editing therapy specifically designed to eliminate the root cause of chronic hepatitis B, cccDNA, and is expected to offer patients a potential cure, fundamentally changing the treatment landscape for chronic hepatitis B.
- Strong Investigator Interest: The late breaker oral presentation of PBGENE-HBV at The Liver Conference 2025 generated significant interest, and the new trial sites are anticipated to further drive investigator engagement and the success of the clinical trial.
See More
Precision BioSciences to Participate in 2026 Needham Virtual Healthcare Conference
- Conference Participation: Precision BioSciences will participate in the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, at 9:30 AM ET, showcasing its latest advancements in gene editing to attract investor and industry attention, thereby enhancing the company's visibility.
- Platform Advantages: The company utilizes its proprietary ARCUS® gene editing platform, focusing on developing therapies for high unmet need diseases, with ARCUS aiming for more precise gene cuts and simpler structures to achieve more defined therapeutic outcomes.
- Product Pipeline Overview: Precision's pipeline includes multiple clinical-stage gene editing candidates designed to deliver lasting cures for genetic and infectious diseases lacking effective treatments, highlighting the company's potential and market demand in the gene therapy sector.
- Follow-Up Opportunities: A replay of the presentation will be available on the company's website in the Investors section after the conference, encouraging interested investors to reach out to the Precision team for further collaboration discussions.
See More
iECURE's ECUR-506 Selected for FDA CMC Program
- FDA Program Participation: iECURE's ECUR-506 has been selected by the FDA to participate in the Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot Program, which is expected to enhance engagement with the FDA, thereby accelerating clinical development and strengthening the company's competitive position in the neonatal OTC deficiency treatment market.
- Clinical Trial Progress: ECUR-506 is currently being evaluated in the OTC-HOPE clinical trial for male infants with neonatal-onset OTC deficiency, having received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations, with promising clinical responses observed, and additional data expected to be released in the first half of 2026.
- Manufacturing Capability Enhancement: Participation in the FDA's CMC program will enable iECURE to improve its manufacturing capabilities while advancing ECUR-506, ensuring that production readiness aligns with clinical progress ahead of a potential Biologics License Application (BLA) submission to meet market demand.
- Strategic Importance: iECURE's CEO Joe Truitt emphasized that the selection for this program underscores the critical importance of aligning clinical progress with manufacturing readiness in developing complex genetic medicines, aiming to bring ECUR-506 to market swiftly to benefit newborn patients.
See More
Precision BioSciences Q4 Earnings Exceed Expectations
- Strong Performance: Precision BioSciences reported a Q4 GAAP EPS of $1.05, beating expectations by $1.59, which highlights a significant improvement in profitability and boosts investor confidence.
- Revenue Surge: The company achieved revenues of $34 million, exceeding market expectations by $24.93 million, indicating robust demand for its products and services, potentially driving future business expansion.
- Positive Stock Reaction: Following the earnings release, Precision BioSciences' shares rose by 8%, reflecting the market's favorable response to its financial performance, which may attract more investor interest.
- Future Outlook: The company anticipates providing potential proof-of-concept data for an HBV cure in 2026, which could drive long-term growth and further solidify its position in the biopharmaceutical sector.
See More
Precision BioSciences Unveils PBGENE-HBV Clinical Data at AASLD
- Clinical Trial Progress: The Phase 1 data for PBGENE-HBV presented at AASLD indicates that 13 patients have been treated across the first five cohorts, demonstrating good safety and tolerability, with dose-dependent antiviral activity, marking a significant advancement in chronic hepatitis B treatment.
- Successful Fundraising: The company raised $75 million in November 2025, extending its cash runway through 2028 to support multiple clinical inflection points for PBGENE-HBV and PBGENE-DMD, enhancing financial stability.
- IND Approval and New Trial Launch: PBGENE-DMD received IND clearance from the FDA in 2026, allowing the initiation of the Phase 1/2 FUNCTION-DMD clinical trial, with initial data from multiple patients expected by year-end 2026, further advancing treatment for Duchenne muscular dystrophy.
- Enhanced Patent Protection: In March 2026, the company received two Notices of Allowance related to PBGENE-HBV, extending patent expiration to 2044, ensuring competitive advantage in hepatitis B treatment.
See More
Precision BioSciences Presents New Hepatitis Treatment Data
- Clinical Trial Progress: Precision BioSciences will present new clinical biopsy data from the ELIMINATE-B trial at the 2026 EASL Congress, demonstrating for the first time that PBGENE-HBV can eliminate cccDNA in the livers of chronic hepatitis B patients, marking a significant breakthrough that may offer hope for a cure.
- Therapeutic Potential: PBGENE-HBV is the world's first clinical trial targeting cccDNA through gene editing, designed to eliminate the root cause of chronic hepatitis B, and has received Fast Track designation from the FDA, highlighting its potential importance in treatment.
- Conference Highlights: The study will be showcased in a poster presentation on May 27, 2026, with abstract number LB26-51656, expected to attract significant attention and potentially boost investor confidence in the company's future developments.
- Market Outlook: Given the urgent need for effective treatments among chronic hepatitis B patients, the success of PBGENE-HBV could significantly enhance Precision BioSciences' competitiveness in the biopharmaceutical market, further solidifying its leadership position in the gene editing field.
See More
Precision BioSciences Expands ELIMINATE-B Trial into France and Romania
- Clinical Trial Expansion: Precision BioSciences has received Clinical Trial Application approval to expand the ELIMINATE-B trial into France and Romania, which is expected to significantly increase patient enrollment and support the clinical execution of PBGENE-HBV.
- Global Footprint Enhancement: This expansion adds multiple clinical trial sites in Europe to the ELIMINATE-B trial, including the UK, Moldova, New Zealand, and the US, thereby enhancing the company's international presence and influence.
- Increased Treatment Potential: PBGENE-HBV is the first gene editing therapy specifically designed to eliminate the root cause of chronic hepatitis B, cccDNA, and is expected to offer patients a potential cure, fundamentally changing the treatment landscape for chronic hepatitis B.
- Strong Investigator Interest: The late breaker oral presentation of PBGENE-HBV at The Liver Conference 2025 generated significant interest, and the new trial sites are anticipated to further drive investigator engagement and the success of the clinical trial.
See More
Precision BioSciences to Participate in 2026 Needham Virtual Healthcare Conference
- Conference Participation: Precision BioSciences will participate in the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, at 9:30 AM ET, showcasing its latest advancements in gene editing to attract investor and industry attention, thereby enhancing the company's visibility.
- Platform Advantages: The company utilizes its proprietary ARCUS® gene editing platform, focusing on developing therapies for high unmet need diseases, with ARCUS aiming for more precise gene cuts and simpler structures to achieve more defined therapeutic outcomes.
- Product Pipeline Overview: Precision's pipeline includes multiple clinical-stage gene editing candidates designed to deliver lasting cures for genetic and infectious diseases lacking effective treatments, highlighting the company's potential and market demand in the gene therapy sector.
- Follow-Up Opportunities: A replay of the presentation will be available on the company's website in the Investors section after the conference, encouraging interested investors to reach out to the Precision team for further collaboration discussions.
See More
iECURE's ECUR-506 Selected for FDA CMC Program
- FDA Program Participation: iECURE's ECUR-506 has been selected by the FDA to participate in the Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot Program, which is expected to enhance engagement with the FDA, thereby accelerating clinical development and strengthening the company's competitive position in the neonatal OTC deficiency treatment market.
- Clinical Trial Progress: ECUR-506 is currently being evaluated in the OTC-HOPE clinical trial for male infants with neonatal-onset OTC deficiency, having received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations, with promising clinical responses observed, and additional data expected to be released in the first half of 2026.
- Manufacturing Capability Enhancement: Participation in the FDA's CMC program will enable iECURE to improve its manufacturing capabilities while advancing ECUR-506, ensuring that production readiness aligns with clinical progress ahead of a potential Biologics License Application (BLA) submission to meet market demand.
- Strategic Importance: iECURE's CEO Joe Truitt emphasized that the selection for this program underscores the critical importance of aligning clinical progress with manufacturing readiness in developing complex genetic medicines, aiming to bring ECUR-506 to market swiftly to benefit newborn patients.
See More
Precision BioSciences Q4 Earnings Exceed Expectations
- Strong Performance: Precision BioSciences reported a Q4 GAAP EPS of $1.05, beating expectations by $1.59, which highlights a significant improvement in profitability and boosts investor confidence.
- Revenue Surge: The company achieved revenues of $34 million, exceeding market expectations by $24.93 million, indicating robust demand for its products and services, potentially driving future business expansion.
- Positive Stock Reaction: Following the earnings release, Precision BioSciences' shares rose by 8%, reflecting the market's favorable response to its financial performance, which may attract more investor interest.
- Future Outlook: The company anticipates providing potential proof-of-concept data for an HBV cure in 2026, which could drive long-term growth and further solidify its position in the biopharmaceutical sector.
See More
Precision BioSciences Unveils PBGENE-HBV Clinical Data at AASLD
- Clinical Trial Progress: The Phase 1 data for PBGENE-HBV presented at AASLD indicates that 13 patients have been treated across the first five cohorts, demonstrating good safety and tolerability, with dose-dependent antiviral activity, marking a significant advancement in chronic hepatitis B treatment.
- Successful Fundraising: The company raised $75 million in November 2025, extending its cash runway through 2028 to support multiple clinical inflection points for PBGENE-HBV and PBGENE-DMD, enhancing financial stability.
- IND Approval and New Trial Launch: PBGENE-DMD received IND clearance from the FDA in 2026, allowing the initiation of the Phase 1/2 FUNCTION-DMD clinical trial, with initial data from multiple patients expected by year-end 2026, further advancing treatment for Duchenne muscular dystrophy.
- Enhanced Patent Protection: In March 2026, the company received two Notices of Allowance related to PBGENE-HBV, extending patent expiration to 2044, ensuring competitive advantage in hepatitis B treatment.
See More
